Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Matthew M. Heeney; David C Rees; Slimane Allali; Isaac Odame; Rodolfo D Cançado; Adlette Inati; Elena Cela; Deborah Keefe; Evgeniya Reshetnyak; Velusamy Shanmuganathan Muthusamy; Lidiya Bebrevska; Michele L Nassin; Julie Kanter

Journal ArticleOPEN ACCESS

Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Heeney M
Rees D
Allali S
et al.

Blood (2024) 144(Supplement 1) 180-180

DOI: 10.1182/blood-2024-207207

N/ACitations

5Readers

Abstract

Conference abstract (ASH 2024; Blood 144 Suppl 1:180). Interim 2-year data from SOLACE-Kids (NCT03474965; EudraCT 2017-001747-12) for patients aged 6 to <12 years with SCD. Earlier SOLACE-Kids data (2-year analysis; 50 patients, ages 12–<18) showed crizanlizumab 5.0 mg/kg safe and well tolerated with clinically relevant reduction in median annualised VOC rate vs baseline. Updated 2-year data on younger cohort extends safety/efficacy characterisation in this age group.

Cite

CITATION STYLE

APA

Heeney, M. M., Rees, D. C., Allali, S., Odame, I., Cançado, R. D., Inati, A., … Kanter, J. (2024). Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study. Blood, 144(Supplement 1), 180–180. https://doi.org/10.1182/blood-2024-207207

Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Abstract

Cite

Register to see more suggestions